Eli Lilly and Company (NYSE:LLY) Trading 1.1% Higher – What’s Next?

Eli Lilly and Company (NYSE:LLY) shares rose 1.1% during mid-day trading on Monday . The company traded as high as $1,170.90 and last traded at $1,165.62. Approximately 2,200,005 shares traded hands during trading, a decline of 27% from the average daily volume of 3,018,681 shares. The stock had previously closed at $1,152.93.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CEO David Ricks said approximately 700,000 seniors began GLP-1 treatment after new Medicare coverage launched in July, with about 70% using Lilly medicines. The data suggests Medicare could materially expand the company’s addressable obesity-treatment market. Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage
• Positive Sentiment: Lilly said one-third of new GLP-1 pill patients are taking Foundayo, its oral obesity drug, and that it is increasing production. Strong early adoption could diversify growth beyond injectable treatments and support future revenue. Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo
• Positive Sentiment: The company is breaking ground on a planned $6.5 billion manufacturing facility in Houston, scheduled for completion in 2030. The investment should expand long-term supply capacity for obesity medicines, though it also increases capital spending. Eli Lilly to host groundbreaking of $6.5 billion facility at Houston’s Generation Park
• Positive Sentiment: An updated valuation estimate raised Lilly’s fair value to $1,325.39 from $1,297.31, reflecting continued analyst support for GLP-1 growth. Eli Lilly stock fair value edges higher
• Neutral Sentiment: Lilly completed a clinical study of LY3971297, an early-stage cardio-metabolic candidate. The update advances the pipeline but provided no immediate efficacy or approval catalyst. Lilly’s LY3971297 trial completion signals next steps
• Negative Sentiment: Competitive pressure remains a risk after Novo Nordisk reported Phase 3 CagriSema results that outperformed Lilly’s tirzepatide in weight loss. Novo’s weak market reaction suggests broader concerns about the obesity-drug market, while Lilly’s stock has also recently lagged the broader market. Novo Nordisk falls as competition fears persist

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on LLY. Bank of America raised their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research note on Friday, July 10th. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. HSBC increased their price target on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. Citigroup lifted their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, Jefferies Financial Group upped their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,305.25.

Eli Lilly and Company Trading Up 1.1%

The firm’s 50-day simple moving average is $1,176.90 and its 200-day simple moving average is $1,077.21. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm has a market capitalization of $1.10 trillion, a PE ratio of 39.11, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the previous year, the business earned $6.31 earnings per share. The company’s quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts expect that Eli Lilly and Company will post 36.54 earnings per share for the current year.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently modified their holdings of the company. Integrity Financial Corp WA grew its holdings in Eli Lilly and Company by 1.3% during the second quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock valued at $767,000 after purchasing an additional 8 shares during the period. Willner & Heller LLC grew its stake in shares of Eli Lilly and Company by 1.0% during the 2nd quarter. Willner & Heller LLC now owns 917 shares of the company’s stock valued at $1,100,000 after acquiring an additional 9 shares during the period. Aspiring Ventures LLC increased its holdings in Eli Lilly and Company by 3.7% in the 2nd quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock worth $306,000 after acquiring an additional 9 shares in the last quarter. Wealthspan Partners LLC increased its holdings in Eli Lilly and Company by 0.4% in the 2nd quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock worth $2,543,000 after acquiring an additional 9 shares in the last quarter. Finally, Navigoe LLC raised its stake in Eli Lilly and Company by 8.7% during the 2nd quarter. Navigoe LLC now owns 113 shares of the company’s stock worth $135,000 after acquiring an additional 9 shares during the period. 82.53% of the stock is owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.